Condition: Pancreatic Cancer · Sponsor: Merrimack Pharmaceuticals
The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-1.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Ctr. | Gilbert, Arizona, United States | — |
| Pacific Cancer Medical Center, Inc. | Anaheim, California, United States | — |
| St. Jude Heritage Healthcare | Fullerton, California, United States | — |
| UCLA School of Medicine | Los Angeles, California, United States | — |
| Cancer Care Assoc Med Grp | Redondo Beach, California, United States | — |
| UCSF Cancer Center | San Francisco, California, United States | — |
| Sansum Clinic | Santa Barbara, California, United States | — |
| Central Coast Med Onc Corp | Santa Maria, California, United States | — |
| Rocky Mountain Cancer Centers | Aurora, Colorado, United States | — |
| Baptist Health Med Gr Onc, LLC | Miami, Florida, United States | — |
| Florida Cancer AffiliatesOcala | Ocala, Florida, United States | — |
| Memorial Regional Hospital | Pembroke Pines, Florida, United States | — |
+ 54 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02399137